详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report

54| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Centre, Afliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu 610041, China

出处：

DOI：

ISSN：

关键词： NSCLC BRAF Non-V600 p T599dup Case report

摘要：

BRAF mutations are found in 1-5% of non-small-cell lung cancer (NSCLC), with V600 and non-V600 accounting for approximately 50% each. It has been confirmed that targeted therapy with dabrafenib + trametinib is effective in patients with metastatic NSCLC carrying BRAF V600E mutations. Preclinical studies have shown that dabrafenib + trametinib may also have inhibitory effects on some types of non-V600E mutations, especially some class II BRAF mutations. However, the efficacy of dabrafenib + trametinib on non-V600E mutant NSCLC in clinical practice only exists in some case reports. Here, we report a case of NSCLC patient carrying BRAF ex15 p.T599dup, who showed a clinical response to the combined therapy of dabrafenib + trametinib.© 2024. The Author(s).

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 3 区医学

小类 | 4 区肿瘤学

最新[2023]版：

大类 | 3 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2023]版：

Q3 ONCOLOGY

最新[2023]版：

Q3 ONCOLOGY

影响因子： 2.7 最新[2023版] 3.1 最新五年平均 2.7 出版当年[2023版] 0 出版当年五年平均 2.7 出版前一年[2023版]

第一作者：

第一作者机构： [1]Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Centre, Afliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu 610041, China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-rearranged NSCLC: a Case Report. [2]BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-rearranged NSCLC: a Case Report. [3]BRAF V600突变型非小细胞肺癌的治疗进展 [4]A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report [5]Clinical characteristics from a case of primary neuroendocrine carcinoma in the renal pelvis [6]A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report [7]Case Report: Primary lymphoepithelioma-like intrahepatic cholangiocarcinoma [8]Safety and Efficacy of Dabrafenib Plus Trametinib in Chinese Patients With BRAF V600E-Mutation Positive Metastatic NSCLC [9]Ectopic thyroid of the pancreatic head: A case report [10]Atezolizumab-induced psoriasis in a patient with metastatic lung cancer-a case report